Adamas Pharmaceuticals Inc.

NASDAQ: ADMSHealthcare / Drugs - Generic / USA
6.20-0.2200-3.43%Vol 201 6541Y Perf -72.45%
Aug 19th, 2019 16:00
BID6.19 ASK6.20
Open6.50 Previous Close6.42
Pre-Market- After-Trading6.18
 - -%  -0.02 -0.32%
Target Price
13.29 
Analyst Rating
Moderate Buy 2.11
Potencial %
114.36 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12M
-100/-100/-73 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-100/-36 
Growth Ranking
★★+     46.91
Insiders Shares Cnt. % 3/6/12M
-100/-100/-54 
Income Ranking
 —    -
Market Cap (mil)172 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
10.44 
Earnings Date
8th Aug 2019

Today's Price Range

6.156.66

52wk Range

4.2023.36

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
6.12%
1 Month
7.18%
3 Months
12.04%
6 Months
-39.03%
1 Year
-72.45%
3 Years
-53.91%
5 Years
-63.21%
10 Years
-

Name / TickerPriceChg.Chg.%
ADMS6.20-0.2200-3.43
AAPL210.353.85001.86
GOOG1 198.4520.85001.77
MSFT138.412.28001.67
XOM69.451.15001.68
WFC45.250.86001.94
JNJ132.250.89000.68
FB186.172.47001.34
GE8.67-0.1200-1.37
JPM108.690.97000.90
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.98-0.908.16
Q01 2019-1.13-1.084.42
Q04 2018-1.36-1.0622.06
Q03 2018-1.34-1.228.96
Q02 2018-1.41-1.2610.64
Q01 2018-1.38-1.352.17
Q04 2017-1.15-1.27-10.43
Q03 2017-1.03-1.04-0.97
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.896.32Positive
12/2019 QR-0.847.69Positive
12/2019 FY-3.743.36Positive
12/2020 FY-2.39-3.02Negative
Next Report Date-
Estimated EPS Next Report-0.98
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume201 654
Shares Outstanding (in ths.)27 771
Trades Count3 634
Dollar Volume5 157 781
Avg. Volume454 772
Avg. Weekly Volume388 601
Avg. Monthly Volume350 455
Avg. Quarterly Volume351 322
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (55.56 %)
5 (55.56 %)
5 (55.56 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
3 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
RatingModerate Buy
2.11
Moderate Buy
2.11
Moderate Buy
2.11

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Gregory T. Went

Teplephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

38%62%

Bearish Bullish

49%51%

News